Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Gains from Sales and Divestitures (2023 - 2025)

CorMedix has reported Gains from Sales and Divestitures over the past 3 years, most recently at $371166.0 for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $371166.0 for Q4 2025, up 154.97% from a year ago — trailing twelve months through Dec 2025 was $371166.0 (up 154.97% YoY), and the annual figure for FY2025 was $371166.0, up 154.97%.
  • Gains from Sales and Divestitures reached $371166.0 in Q4 2025 per CRMD's latest filing, up from $145574.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $371166.0 in Q4 2025 and bottomed at $42844.0 in Q2 2024.
  • Median Gains from Sales and Divestitures over the past 3 years was $103734.0 (2023), compared with a mean of $141232.4.
  • The largest annual shift saw Gains from Sales and Divestitures soared 40.33% in 2024 before it skyrocketed 154.97% in 2025.
  • Over 3 years, Gains from Sales and Divestitures stood at $103734.0 in 2023, then skyrocketed by 40.33% to $145574.0 in 2024, then surged by 154.97% to $371166.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for CRMD at $371166.0 in Q4 2025, $145574.0 in Q4 2024, and $42844.0 in Q3 2024.